Volume 28, Supplement—December 2022
SUPPLEMENT ISSUE
Surveillance
SARS-CoV-2 Prevalence in Malawi Based on Data from Survey of Communities and Health Workers in 5 High-Burden Districts, October 2020
Table 1
Characteristic | Community participants, n = 4,261 |
Health facility staff, N = 970 |
Total, N = 5,231 | |||
---|---|---|---|---|---|---|
No. (%) | Weighted proportion (95% CI) | No. (%) | Weighted proportion (95% CI) | |||
Sex | ||||||
M | 1,524 (35.8) | 36.6 (32.8–40.6) | 428 (44.1) | 47.5 (39–56) | 1,952 | |
F |
2,737 (64.2) |
63.4 (59.4–67.2) |
542 (55.9) |
52.5 (44–61) |
3,279 |
|
Age, y | ||||||
10–19 | 982 (23.0) | 20.1 (18.0–22.4) | 8 (0.8) | 0.4 (0.1–1.5) | 990 | |
20–29 | 1,085 (25.5) | 23.8 (21.9–25.8) | 291 (30.0) | 20.0 (14.8–26.3) | 1,376 | |
30–39 | 887 (20.8) | 21.7 (19.4–24.3) | 335 (34.5) | 38.7 (33.1–44.6) | 1,222 | |
40–49 | 626 (14.7) | 16.8 (15.1–18.7) | 236 (24.3) | 25.9 (22.6–29.5) | 862 | |
≥50 |
681 (16) |
17.5 (15.5–19.8) |
100 (10.3) |
15.0 (9.6–22.6) |
781 |
|
District | ||||||
Blantyre | 535 (12.6) | 16.0 (13.0–19.6) | 163 (16.8) | 15.1 (7.9–27.0) | 698 | |
Karonga | 1,092 (25.6) | 8.5 (7.2–10.1) | 132 (13.6) | 19.9 (11.5–32.1) | 1,224 | |
Lilongwe | 560 (13.1) | 37.8 (29.9–46.5) | 216 (22.3) | 23.6 (17.8–30.5) | 776 | |
Mangochi | 937 (22.0) | 23.9 (19.8–28.6) | 191 (19.7) | 9.5 (7.2–12.4) | 1,128 | |
Mzimba North |
1,137 (26.7) |
13.7 (11.4–16.4) |
268 (27.6) |
31.9 (22.6–42.9) |
1,405 |
|
Location type | ||||||
Rural | 1,505 (35.3) | 50.5 (38.3–62.5) | 406 (41.9) | 35.2 (32.1–38.2) | 1,911 | |
Urban |
2,756 (64.7) |
49.5 (37.5–61.6) |
564 (58.1) |
64.7 (61.6–67.7) |
3,320 |
|
Household size, categorical | ||||||
1–2 | 500 (11.7) | 15.1 (11.5–19.6) | 241 (24.8) | 23.5 (17.7–30.5) | 741 | |
3–4 | 1,888 (44.3) | 44.1 (41.1–47.1) | 331 (34.1) | 34.5 (29.4–40.1) | 2,219 | |
≥5 |
1,872 (43.9) |
40.8 (36.9–44.8) |
398 (41.0) |
42.0 (36.0–48.1) |
2,270 |
|
Education† | ||||||
No education | 339 (8.0) | 12.8 (8.8–18.2) | 0 | 0 | 339 | |
Primary | 2,138 (50.5) | 53.3 (48.0–58.5) | 51 (5.3) | 4.6 (2.5–8.4) | 2,189 | |
Secondary | 15,250 (35.9) | 29.0 (25.0–33.4) | 485 (50.0) | 58.9 (51.5–66.0) | 2,005 | |
Tertiary/postsecondary |
237 (5.6) |
4.9 (3.7–6.5) |
434 (44.7) |
36.5 (29.3–44.3) |
671 |
|
Occupation | ||||||
Student | 950 (22.3) | 18.5 (16.4–20.8) | NA | NA | 950 | |
Unemployed | 1,704 (40.0) | 46.0 (40.8–51.2) | NA | NA | 1,704 | |
Employed, HFS | 30 (0.7) | 0.98 (0.7–1.4) | 970 | 970 | 65 | |
Employed, non-HFS | 275 (6.5) | 0.54 (0.3–0.9) | NA | NA | 30 | |
Retired | 65 (1.5) | 7.0 (5.4–9.1) | NA | NA | 275 | |
Other |
1,237 (29.0) |
27.0 (22.6–31.9) |
NA |
NA |
1,237 |
|
Preexisting medical conditions | ||||||
Any medical condition | 472 (11.1) | 11.2 (9.6–13.0) | 175 (18.0) | 23.9 (19.6–28.9) | 647 | |
Diabetes mellitus | 38 (0.9) | 0.7 (0.4–1.1) | 11 (1.1) | 0.7 (0.3–1.6) | 49 | |
CVD, including hypertension | 224 (5.3) | 5.5 (4.3–6.9) | 68 (7.0) | 10.5 (6.3–16.9) | 292 | |
Renal disease | 2 (0) | 0.04 (0.01–0.21) | 4 (0.4 | 1.0 (0.3–3.2) | 6 | |
Immunosuppressive condition‡ | 78 (1.9) | 1.8 (1.3–2.5) | 39 (4.0%) | 5.7 (2.6–11.8) | 117 | |
Obesity | 12 (0.3) | 0.2 (0.1–0.4) | 10 (1.0) | 0.6 (0.2–1.4) | 22 | |
Asthma | 104 (2.5) | 2.4 (1.8–3.2) | 47 (4.8) | 6.9 (4.4–10.4) | 151 | |
Chronic lung disease, including COPD | 8 (0.2) | 0.08 (0.04–0.2) | 2 (0.2) | 0.1 (0.03–0.5) | 10 | |
Liver disease | 3 (0.1) | 0.05 (0.01–0.20) | 2 (0.2) | 1.0 (0.15–6.0) | 5 | |
Other disease | 65 (1.6) | 2.1 (1.5–2.9) | 11 (1.1) | 1.4 (0.46–4.2) | 76 |
*COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; HFS, health facility staff; NA, not applicable. †The highest level of education attained. Primary education = 8 y; secondary education = 4 y; tertiary/postsecondary = college/university education. ‡From cancer, chemotherapy, radiation therapy, immunosuppressive medications, self-reported HIV, organ transplant, or inherited immunodeficiency.
1These first authors contributed equally to this article.
2These senior authors contributed equally to this article.
3Members are listed at the end of this article.
Page created: July 01, 2022
Page updated: December 11, 2022
Page reviewed: December 11, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.